Compare VSME & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | SNOA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.1M |
| IPO Year | 2022 | 2006 |
| Metric | VSME | SNOA |
|---|---|---|
| Price | $1.20 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 226.8K | 12.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,288,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $0.07 | $1.77 |
| 52 Week High | $3.21 | $6.92 |
| Indicator | VSME | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | N/A |
| Support Level | $1.05 | N/A |
| Resistance Level | $1.21 | N/A |
| Average True Range (ATR) | 0.22 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 20.49 | 0.00 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.